drugset
drugset / Trial / NCT05862974

A Dose-escalation Study of LPM3480392 in Chinese Healthy Subjects

NCT05862974 ↗

Phase 1 Completed 80 enrolled Luye Pharma Group Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, dose-increasing Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single intravenous infusion of LPM3480392 injection in healthy subject

Timeline

Start
2021-02-25
Primary completion
2021-11-02
Completion
2021-11-02

Drugs

EvaluationDrugModalityDoseRoute
Subject LPM3480392 Unknown 1 mg Intravenous
Subject LPM3480392 Unknown 2 mg Intravenous
Subject LPM3480392 Unknown 3 mg Intravenous
Subject LPM3480392 Unknown 4 mg Intravenous
Subject LPM3480392 Unknown 5 mg Intravenous
Subject LPM3480392 Unknown 6 mg Intravenous
Subject LPM3480392 Unknown 7 mg Intravenous
Subject LPM3480392 Unknown 8 mg Intravenous

Indications

No indication recorded.